Studying Crohn's disease risk in relatives of people with the disease
Studies blood and lifestyle factors to predict Crohn's disease in young adult relatives.
Plain-language title generated from the registry record
Registry title: Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives
Key facts
- Where
- Lisbon, PortugalSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 35 years old?
Source: NCT07316621, who can take part
Where in Portugal
- Hospital Beatriz ÂngeloLisbon, PortugalTaking people
- Hospital da Luz LisboaLisbon, PortugalTaking people
- Hospital dos CapuchosLisbon, PortugalTaking people
- Hospital Santa MariaLisbon, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GLSMED Learning Health S.A.
- Trial code
- NCT07316621
- Record updated
- 29 July 2026
- Original description
The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease.Read full original descriptionShow less
Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives
The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease.
This study will be conducted within Work Package 3 (WP3) of the INTERCEPT project, a consortium funded by the Innovative Health Initiative (IHI). The research will take place across 28 centres in seven countries: Portugal, Spain, France, Italy, the Netherlands, Sweden, and Poland.
To achieve the study objectives, individuals with Crohn's disease (referred to as patients) will be invited to participate and to engage their eligible first-degree relatives. At the baseline visit, the patient's physician will complete a clinical questionnaire covering disease history, treatments, and previous interventions.
At the same time, first-degree relatives (parents, siblings, or children) will donate a blood sample for serum isolation and, optionally, a whole blood and stool sample. They will also complete a questionnaire regarding their health status, habits, and preferences. Follow-up questionnaires will be administered every six months to monitor the onset of symptoms or behavioural changes.
Inclusion: Male or female participants, between 16 and 35 years old; FDR (parent, full-siblings or offspring) from a patient with an established diagnosis of CD; Participants able to understand the information provided to them and to give written informed assent or consent for the study.
Exclusion: Prior diagnosis of IBD; Any legal or medical condition that limits the information and participation in the study; Participants unwilling or unable to donate blood for serum; Inability to verify CD diagnosis in the proband; Participants unwilling or unable to provide informed written consent.